<SEC-DOCUMENT>0000950170-25-009848.txt : 20250128
<SEC-HEADER>0000950170-25-009848.hdr.sgml : 20250128
<ACCEPTANCE-DATETIME>20250128163004
ACCESSION NUMBER:		0000950170-25-009848
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250128
DATE AS OF CHANGE:		20250128

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuphoria Therapeutics Inc.
		CENTRAL INDEX KEY:			0001191070
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93208
		FILM NUMBER:		25564630

	BUSINESS ADDRESS:	
		STREET 1:		100 SUMMIT DR
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803
		BUSINESS PHONE:		781-439-5551

	MAIL ADDRESS:	
		STREET 1:		100 SUMMIT DR
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIONOMICS LIMITED/FI
		DATE OF NAME CHANGE:	20020920

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apeiron Investment Group Ltd.
		CENTRAL INDEX KEY:			0001845711
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			O1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		BLOCK A, APT.12
		STREET 2:		IL-PIAZZETTA, TOWER ROAD
		CITY:			SLIEMA
		STATE:			O1
		ZIP:			SLM1605
		BUSINESS PHONE:		44 7557 251 563

	MAIL ADDRESS:	
		STREET 1:		BLOCK A, APT.12
		STREET 2:		IL-PIAZZETTA, TOWER ROAD
		CITY:			SLIEMA
		STATE:			O1
		ZIP:			SLM1605
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001193125-21-370636</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001845711</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>01/24/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001191070</issuerCIK>
        <issuerCUSIP>64136E102</issuerCUSIP>
        <issuerName>Neuphoria Therapeutics Inc.</issuerName>
        <address>
          <street1 xmlns="http://www.sec.gov/edgar/common">100 Summit Dr</street1>
          <city xmlns="http://www.sec.gov/edgar/common">Burlington</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">01803</zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Julien Hofer</personName>
          <personPhoneNum>356 9960 9158</personPhoneNum>
          <personAddress>
            <street1 xmlns="http://www.sec.gov/edgar/common">Beatrice, at 66 &amp; 67 Amery Street</street1>
            <city xmlns="http://www.sec.gov/edgar/common">Sliema</city>
            <stateOrCountry xmlns="http://www.sec.gov/edgar/common">O1</stateOrCountry>
            <zipCode xmlns="http://www.sec.gov/edgar/common">SLM1707</zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001845711</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Apeiron Investment Group Ltd.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>O1</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>72618</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>72618</sharedDispositivePower>
        <aggregateAmountOwned>72618</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.5</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001840676</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Apeiron Presight Capital Fund II, L.P.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>0</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Presight Capital Management I, L.L.C.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>0</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Fabian Hansen</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>0</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001845872</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Christian Angermayer</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>2M</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>72618</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>72618</sharedDispositivePower>
        <aggregateAmountOwned>72618</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.5</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>Neuphoria Therapeutics Inc.</issuerName>
        <issuerPrincipalAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">100 Summit Dr</street1>
          <city xmlns="http://www.sec.gov/edgar/common">Burlington</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">01803</zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 2 to Schedule 13D (this "Amendment No. 2") amends and supplements the statement on Schedule 13D filed with the United States Securities and Exchange Commission (the "SEC") on December 30, 2021, as amended to date (the "Schedule 13D"), relating to the ordinary shares, no par value per share (the "Ordinary Shares"), of Bionomics Limited, an Australian public company limited by shares. On December 23, 2024 (the "Effective Date"), the redomiciliation ("Redomiciliation") of Bionomics Limited was implemented under Australian law in accordance with a Scheme Implementation Agreement (as amended) between Bionomics and Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria" or, the "Issuer"). The Redomiciliation was effected pursuant to a statutory Scheme of Arrangement under Australian law (the "Scheme"). As a result of the Redomiciliation, Bionomics became a wholly-owned subsidiary of Neuphoria, and each outstanding Ordinary Share and ADS were converted into shares of Common Stock, $0.00001 par value per share ("Common Stock") of the Issuer. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D</commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>The information contained on the cover pages is incorporated by reference to this Item 5.

The information on the cover pages sets forth the aggregate number and percentage of shares of Common Stock outstanding beneficially owned by each of the Reporting Persons, based on 1,628,659 shares of Common Stock outstanding as of December 31, 2024.</percentageOfClassSecurities>
        <numberOfShares>The information contained on the cover pages is incorporated by reference to this Item 5.

Apeiron is the record holder of the shares of Common Stock reported herein. Christian Angermayer is the majority shareholder of Apeiron and may be deemed to share beneficial ownership of the securities beneficially owned by Apeiron.</numberOfShares>
        <transactionDesc>On January 24, 2025, Apeiron sold 55,414 shares of Common Stock in an open market transaction on the Nasdaq Global Market at an average price per share of $10.8428. Except for the foregoing, during the past 60 days neither the Reporting Persons nor any Related Person has effected any transactions in the Ordinary Shares.</transactionDesc>
        <listOfShareholders>None.</listOfShareholders>
        <date5PercentOwnership>This Amendment No. 2 is being filed to report that, as of the date hereof, the Reporting Persons do not beneficially own more than five percent of the outstanding Common Stock.</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Apeiron Investment Group Ltd.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Mario Frendo</signature>
          <title>Mario Frendo, Director</title>
          <date>01/28/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Apeiron Presight Capital Fund II, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>By: Presight Capital Management I, L.L.C., its general partner; /s/ Fabian Hansen</signature>
          <title>Fabian Hansen, Managing Member</title>
          <date>01/28/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Presight Capital Management I, L.L.C.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Fabian Hansen</signature>
          <title>Fabian Hansen, Managing Member</title>
          <date>01/28/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Fabian Hansen</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Fabian Hansen</signature>
          <title>Fabian Hansen</title>
          <date>01/28/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Christian Angermayer</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Christian Angermayer</signature>
          <title>Christian Angermayer</title>
          <date>01/28/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
